Deepak Almeida

List of Publications by Year
in descending order

18	1,088	687363 13	888059 17
papers	citations	h-index	g-index

19	19	19	1219
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1522-1524.	3.2	203
2	Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4590-4599.	3.2	165
3	Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4331-4340.	3.2	142
4	Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 2621-2625.	3.2	117
5	Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2009, 53, 4178-4184.	3.2	90
6	Incidence of Multidrug-Resistant Tuberculosis in Urban and Rural India and Implications for Prevention. Clinical Infectious Diseases, 2003, 36, e152-e154.	5.8	81
7	High Incidence of the Beijing Genotype among Multidrug-Resistant Isolates of Mycobacterium tuberculosis in a Tertiary Care Center in Mumbai, India. Clinical Infectious Diseases, 2005, 40, 881-886.	5.8	72
8	Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 989-993.	5.6	61
9	Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Neglected Tropical Diseases, 2011, 5, e933.	3.0	40
10	Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15001-15005.	7.1	33
11	Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules. Journal of Infectious Diseases, 2015, 212, 1827-1834.	4.0	20
12	Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System. Journal of Clinical Microbiology, 2016, 54, 1276-1281.	3.9	16
13	Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0141221.	3.2	16
14	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
15	Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian Journal of Medical Research, 2012, 136, 808-14.	1.0	8
16	An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of Clofazimine. Pharmaceutics, 2022, 14, 17.	4.5	4
17	Quantitative Analysis of the Phase Transition Mechanism Underpinning the Systemic Self-Assembly of a Mechanopharmaceutical Device. Pharmaceutics, 2022, 14, 15.	4.5	4
18	Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. FASEB Journal, 2020, 34, 1-1.	0.5	0